Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial
Diabetes 2022 Apr 01;71(4)812-820, E Wolsk, M Jürgens, M Schou, M Ersbøll, P Hasbak, A Kjær, B Zerahn, NH Brandt, PH Gæde, P Rossing, J Faber, SE Inzucchi, CM Kistorp, F GustafssonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.